Compositions comprising an anti-C5 antibody
AssigneeAlexion Pharmaceuticals, Inc.
InventorYi Wang
Life of this patent
Estimating the term…
Abstract
The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.
Claims4
A pharmaceutical composition comprising 30 mg/mL of an anti-C5 antibody, sodium phosphate at a concentration of 10 mM, sodium chloride at a concentration of 150 mM, and polysorbate 80 at a level of 0.001 to 0.02% by volume, wherein the anti-C5 antibody comprises a variable light chain CDR1 comprising amino acid residues 26-36 of SEQ ID NO:1, a variable light chain CDR2 comprising amino acid residues 52-58 of SEQ ID NO:1, a variable light chain CDR3 comprising amino acid residues 91-99 of SEQ ID NO:1, a variable heavy chain CDR1 comprising amino acid residues 152-161 of SEQ ID NO:1, a variable heavy chain CDR2 comprising amino acid residues 176-192 of SEQ ID NO:1, and a variable heavy chain CDR3 comprising amino acid residues 225-237 of SEQ ID NO:1, and wherein the pH of the composition is between pH 6 and pH 8.
A pharmaceutical composition comprising 30 mg/mL of an anti-C5 antibody, sodium phosphate at a concentration of 10 mM, sodium chloride at a concentration of 150 mM, and polysorbate 80 at a level of 0.001 to 0.02% by volume, wherein the anti-C5 antibody comprises a heavy chain variable region comprising residue numbers 1-122 of SEQ ID NO:
- 2 and a light chain variable region comprising residue numbers 1-108 of SEQ ID NO:
- 3, and wherein the pH of the composition is between pH 6 and pH 8.
Dependencies are inferred from the claim text.